Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).
Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.
Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.
Top-decile sponsor footprint
Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,845 total, page 34 of 37
Assessment Of Safety Of UK-390,957
NCT00219609
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
NCT00147498
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143104
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
NCT00094107
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
NCT00089648
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
NCT00147485
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
NCT00138749
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
NCT00137462
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
NCT00174226
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143338
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
NCT00151476
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00087490
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
NCT00195260
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
NCT00113529
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00084266
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
NCT00141297
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
NCT00094055
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
NCT00091689
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
NCT00083889
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
NCT00471172
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
NCT00138762
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
NCT00712504
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
NCT00134264
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
NCT00483028
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
NCT00219622
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
NCT00220376
Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction
NCT00650039
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
NCT00078000
Rollover Protocol for Prior SU011248 Protocols
NCT00798889
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
NCT00076024
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
NCT00147550
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532
CP-751,871 Treatment For Patients With Multiple Myeloma
NCT01536145
Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.
NCT00136981
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
NCT00078468
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
NCT00075218
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
NCT00147576
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
NCT00072852
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
NCT00134238
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
NCT00134173
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
NCT00076011
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
NCT01740362
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
NCT00074867
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
NCT00715039
A Study Of CP-690,550 In Stable Kidney Transplant Patients
NCT01710033
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 703 |
| Phase 2 | 470 |
| Phase 3 | 411 |
| Phase 4 | 93 |
Therapeutic Areas
What is open in the Pfizer pipeline
106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).
Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).
Top condition: Healthy (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pfizer: open-pipeline peers nationwide
Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,845 trials (± recruiting share)
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Duke University · 1,725 trials · 11% recruiting
- University of California, San Francisco · 1,713 trials · 16% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pacira Pharmaceuticals · 6% recruiting · 88 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this Pfizer page
1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.
- 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.